Dunn Gordon 4
4 · Quoin Pharmaceuticals, Ltd. · Filed Dec 27, 2024
Insider Transaction Report
Form 4
Dunn Gordon
Chief Financial Officer
Transactions
- Purchase
Series G Warrants (right to buy)
2024-12-23+122,221→ 122,221 totalExercise: $0.45From: 2024-12-23Exp: 2029-12-24→ ADS (122,221 underlying) - Purchase
Ordinary Shares
2024-12-23$0.45/sh+122,221$54,999→ 151,077 total - Purchase
Series F Warrants (right to buy)
2024-12-23+122,221→ 122,221 totalExercise: $0.45From: 2024-12-23Exp: 2026-12-23→ ADS (122,221 underlying)
Footnotes (3)
- [F1]Reported securities are represented by American Depositary Shares ("ADSs"). Each ADS represents one ordinary share of the Issuer.
- [F2]Each ADS purchased together with a Series F Warrant to purchase one ADS and a Series G Warrant to purchase one ADS in the Issuer's public offering which closed on December 23, 2024, at a combined public offering price of $0.45. The Series F Warrants and the Series G Warrants are collectively referred to as the "Warrants."
- [F3]The Warrants were exercisable immediately, subject to a beneficial ownership cap.